Sol Gel Technologies Ltd (SLGL)
Sol-Gel Technologies Ltd. is a healthcare company focused on developing topical dermatology treatments for patients with severe skin conditions. Its commercial products include Twyneo, a once-daily non-antibiotic cream for acne vulgaris, and Epsolay, a once-daily topical cream for papulopustular rosacea. The company is also advancing pipeline candidates, including SGT-610, which is in Phase 3 trials for Gorlin syndrome, and SGT-210, which has completed Phase I testing for olmsted syndrome. Sol-Gel works with Padagis Israel Pharmaceuticals Ltd. and has licensing agreements with Galderma Holding SA and Searchlight Pharma Inc. Founded in 1997, the company is headquartered in Ness Ziona, Israel, and its common stock trades on the NASDAQ under the symbol SLGL.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SLGL
|
$64.63
|
-24.8% Downside
|
Overvalued
|
$193
|
124.5% Upside
|
Bargain
|
Great
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-268.9x
|
5.5x
|
15.2x
|
261.8 M
|
229.3 M
|
0.3%
|
16.2%
|
2.7
|
—
|
-26.3%
|
